Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction study of LY3074828 in moderate-to-severe active ulcerative colitis after failure of conventional or biologic therapy
CTR20192153Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mirikizumab in autoimmune colitis, sponsored by Eli Lilly and Company. Started Jan 2020; status: completed.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20192153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192153.